MARKET

IKT

IKT

Inhibikase Therapeutics Inc
NASDAQ
1.900
-0.080
-4.04%
Closed 16:00 04/17 EDT
OPEN
1.960
PREV CLOSE
1.980
HIGH
1.980
LOW
1.840
VOLUME
162.83K
TURNOVER
--
52 WEEK HIGH
4.200
52 WEEK LOW
1.120
MARKET CAP
141.25M
P/E (TTM)
-1.6371
1D
5D
1M
3M
1Y
5Y
1D
Inhibikase Therapeutics Advances PAH Treatment with New Leadership
TipRanks · 5d ago
Inhibikase Therapeutics Appoints New Chief Financial Officer
TipRanks · 5d ago
Inhibikase Names McIntyre Finance Chief as Lees-Rolfe Resigns
Dow Jones · 5d ago
Inhibikase Therapeutics appoints David McIntyre as CFO; shares rise
Seeking Alpha · 5d ago
INHIBIKASE THERAPEUTICS INC - APPOINTMENT OF DAVID MCINTYRE AS CHIEF FINANCIAL OFFICER, EFFECTIVE APRIL 14, 2025
Reuters · 5d ago
Press Release: Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
Dow Jones · 5d ago
*Inhibikase Therapeutics Appoints David McIntyre Chief Fincl Officer >IKT
Dow Jones · 5d ago
Weekly Report: what happened at IKT last week (0407-0411)?
Weekly Report · 6d ago
More
About IKT
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).
Recently
Symbol
Price
%Change

Webull offers Inhibikase Therapeutics Inc stock information, including NASDAQ: IKT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IKT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IKT stock methods without spending real money on the virtual paper trading platform.